Genmab — August 2016
-
arzerra subcu indrulleing starter september
-
hele omkostningsstigningen går til r&d expenses - G&A får kun 2 mio ekstra. Me likes!
-
net financial giver 1 mio skæve - de burde investere i GEN aktier i stedet!!!
-
hexabody dr5 - vidste vi at det var target?
-
Tak for opdatering dingle.
-
omk increase kommer primært fra acceleration af duobody cd20/cd3 mod klinikken
-
axl IND filed i juli...
-
tak dohk
-
Jan taler stadig om nye duo og hexa deals. Han må jo mene det, siden han fortsætter så ufortrødent
-
gad vide om Julie Mead, hsbc er med på CC?
-
omk stigning er pga en mulighed for at få mere produkt fra producenterne - så en acceleration af omkosntinger frem for en egentlig increase
-
men vi får en cost increase i 2017 over 2016 pga investeringer i de 4 programmer
-
launch i tyskland og østrig - 2 andre er lige op over
-
Italien kommer feks først i 2017
-
ingen sales milestones i guidance
-
dara subcut recategorized from phase 1 to 3
-
spm fra sachin fra BoA - vil det give evt. filing i 2017...
-
July strongest month of sales up to now - IMS source
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind